Edition:
United States

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

105.43USD
4:02pm EDT
Change (% chg)

$-0.41 (-0.39%)
Prev Close
$105.84
Open
$105.82
Day's High
$106.15
Day's Low
$105.06
Volume
58,497
Avg. Vol
82,435
52-wk High
$109.41
52-wk Low
$67.21

Latest Key Developments (Source: Significant Developments)

Charles River Laboratories posts Q2 adj. earnings $1.29/shr
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Charles River Laboratories International Inc :Charles River Laboratories announces second-quarter 2017 results from continuing operations.Q2 non-GAAP earnings per share $1.29.Q2 GAAP earnings per share $1.12.Q2 revenue $469.1 million versus I/B/E/S view $458 million.Q2 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Charles River Laboratories International Inc sees 2017 GAAP EPS estimate $4.18-$4.33.Charles River Laboratories International Inc sees 2017 non-GAAP EPS estimate $5.00- $5.15.Charles River Laboratories International Inc sees 2017 revenue growth, organic 7.0 pct - 8.5 pct.Q2 earnings per share view $1.22, revenue view $458.0 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $5.10, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories acquires Brains On-Line
Monday, 7 Aug 2017 07:30am EDT 

Aug 7 (Reuters) - Charles River Laboratories International Inc :Charles river laboratories acquires Brains On-Line.Charles River Laboratories International Inc - ‍purchase price was approximately EUR 18 million in cash​.Charles River Laboratories - ‍In addition to initial purchase price, deal includes potential additional payments of up to eur 6.7 million.Charles River Laboratories International Inc says ‍it has acquired Brains On-Line, a contract research organization​.  Full Article

Charles River Laboratories' Board increase size of board from nine to ten
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Charles River Laboratories International Inc :Charles River Laboratories International - on July 1, board of directors of co increased size of board from nine to ten - SEC filing.  Full Article

Charles River Laboratories reports Q1 non-GAAP earnings per share $1.29
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Charles River Laboratories International Inc : :Charles river laboratories announces first-quarter 2017 results from continuing operations.Q1 non-GAAP earnings per share $1.29.Q1 GAAP earnings per share $0.97.Q1 revenue $445.8 million versus I/B/E/S view $437.1 million.Q1 earnings per share view $1.14 -- Thomson Reuters I/B/E/S.Charles river laboratories international inc sees 2017 revenue growth, reported 7.5pct - 9.0pct.Charles River Laboratories International Inc sees 2017 non-gaap eps estimate $5.00 - $5.15.Sees 2017 GAAP eps estimate of $4.18-$4.33.Charles River Laboratories International Inc - company is maintaining its revenue guidance for 2017.FY2017 earnings per share view $5.06, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.Sees 2017 revenue growth, organic of 7.0pct - 8.5pct.Sees 2017 non-GAAP EPS estimate of $5.00 - $5.15.  Full Article

Nimbus Therapeutics enters strategic partnership with Charles River Laboratories
Wednesday, 5 Apr 2017 08:00am EDT 

Charles River Laboratories International Inc :Nimbus Therapeutics enters into strategic partnership with Charles River Laboratories to advance new therapeutic programs.  Full Article

Charles River Laboratories and Chiesi Farmaceutici announce extension of integrated respiratory drug discovery program
Monday, 13 Mar 2017 08:00am EDT 

Charles River Laboratories International Inc - : Charles River Laboratories and Chiesi Farmaceutici Spa announce extension of integrated respiratory drug discovery program .To provide Chiesi portfolio of drug discovery capabilities to help test Chiesi's candidates for preclinical development.  Full Article

Charles River Labs says acquires Agilux Labs for $64 mln
Wednesday, 28 Sep 2016 04:30pm EDT 

Charles River Laboratories International Inc : Charles river laboratories acquires Agilux Laboratories, Inc . Deal for $64 million . Says acquisition is expected to be neutral to Charles River's non-gaap earnings per share in q4 of 2016 . Agilux will be reported as part of charles river's discovery and safety assessment (dsa) segment . Purchase price was approximately $64 million in cash, . Agilux is expected to generate full-year revenue of $27 million in 2016 .Acquisition is expected to be slightly accretive to non-gaap earnings per share in 2017.  Full Article

Charles River Labs Q2 earnings per share $0.73
Wednesday, 3 Aug 2016 07:00am EDT 

Charles River Laboratories International Inc : Quarter 2016 results from continuing operations . Q2 gaap earnings per share $0.73 from continuing operations . Q2 earnings per share view $1.10 -- Thomson Reuters I/B/E/S . Q2 non-gaap earnings per share $1.20 . Q2 revenue $434.1 million versus i/b/e/s view $425.1 million . Q2 gaap earnings per share $0.73 . Sees 2016 gaap eps of $3.15-$3.25 . 2016 non-gaap eps estimate of $4.40 - $4.50 . 2016 revenue guidance range has been raised by 1% . Sees 2016 revenue growth on reported basis of 20% - 23.5% .Fy2016 earnings per share view $4.39, revenue view $1.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories International Inc reaffirms FY 2016 revenue guidance; increases FY 2016 EPS guidance
Wednesday, 4 May 2016 07:00am EDT 

Charles River Laboratories International Inc:Reaffirming its revenue growth guidance for FY 2016, including contribution from WIL Research.Increases its non-GAAP earnings per share guidance for 2016 to primarily reflect first-quarter performance, better-than-expected operating margin improvement in the RMS segment, and the inclusion of WIL Research from April 4, 2016.Increases guidance for FY 2016 non-GAAP earnings per share to a range of $4.32 to $4.45.  Full Article

Charles River Laboratories International Inc and BioMotiv enter into strategic partnership
Wednesday, 13 Apr 2016 04:30pm EDT 

Charles River Laboratories International Inc:Has entered into a strategic partnership with BioMotiv LLC.Charles River has committed to invest up to $10 million in BioMotiv.Says through agreement, Charles River will be preferred drug discovery and preclinical development partner for BioMotiv's portfolio of technologies and companies.  Full Article